Eargo Review – The Company Is Winding Down. Do Not Buy.

Eargo made small, rechargeable, in-canal over-the-counter hearing aids for adults with perceived mild-to-moderate high-frequency hearing loss. It was FDA-cleared, it was genuinely well designed for the “I do not want anyone to see it” buyer, and it is now winding down. Customer support and warranty processing are committed only through 15 September 2026, with the company stating plainly that it “cannot guarantee the availability of any future support services” after that. There is nothing to buy and no reason to try.

Read This First: Eargo Is Winding Down

We came to this review expecting to compare hearing aid prices. What we found instead was that eargo.com is now a single page. The homepage is a notice to customers. The hearing aids page and the pricing page both returned a redirect back to it. There is no storefront, no product catalogue and no checkout.

We want to be fair about the tone of that notice. It is clear, dated, specific and addressed to customers rather than buried. It gives a phone number, an email address, staffed hours and a date. A great many companies in this position simply go quiet, and Eargo did not. That deserves saying before everything else in this review, which is necessarily about why you should not buy.

What the Notice Actually Says

One practical detail from the notice worth acting on: all future updates will go by email only. The company asks customers to make sure it has a current address on file, updatable through the app or by contacting support. If your Eargo account still has an old email on it, that is the difference between hearing about the warranty transition plan and not.

If You Already Own a Pair, Do This Now

This is the part of the review that is actually useful to somebody. There is a deadline, it is 15 September 2026, and these steps take an afternoon.

To be clear about what is not happening: the notice says the hearing aids “will continue to provide hearing amplification and core functionality”. Nothing suggests they stop working on 15 September. What ends is the safety net.

What Eargo Was, and Who It Was For

Eargo built small rechargeable in-canal hearing aids sold direct to consumers, without the audiologist visit and dispensing fee that traditionally came with the category. Its site lists its current over-the-counter products as Eargo 8, 7, 6, SE and LINK by Eargo. The pitch was cosmetic and practical at once: nearly invisible in the ear, rechargeable rather than fiddling with tiny batteries, and orderable without an appointment.

The buyer was the person who has been putting off doing anything about their hearing, largely because of how hearing aids look and what the process involves. That is a real and large group, and reducing the friction for them was a legitimate contribution.

Pricing: There Is No Longer a Storefront

The one cost fact that matters today is the one the notice implies: the effective total cost of buying an Eargo now is the purchase price plus the cost of replacing it, because you would be buying into a product line with a support horizon measured in weeks. There is no arithmetic that makes that a good purchase.

Historically this category also involved insurance questions, and Eargo’s history there is covered below — it is a substantial part of how the company arrived at this point.

The Regulatory Status, Precisely

Because this is a medical device, we checked the FDA databases directly rather than taking the marketing at its word. The regulatory position was never the problem here, and it is worth stating clearly so nobody misreads this review as a safety alert about the devices themselves.

The over-the-counter hearing aid category itself was created by an FDA final rule published on 17 August 2022. It was a genuinely good piece of consumer policy, opening a market that had been gated behind professional dispensing. Eargo cleared into it properly.

Eligibility, Red Flags and Who Should Not Use One

The federal rule sets the boundaries of who an OTC hearing aid is for. 21 CFR 800.30 defines it as intended for a person aged 18 or older to compensate for perceived mild to moderate hearing impairment, sold “without the supervision, prescription, or other order, involvement, or intervention of a licensed person”.

An OTC hearing aid is not for you if:

• You are under 18. The rule states plainly that “sale to or for a person younger than 18 years of age is prohibited”
• Your hearing loss is more than mild-to-moderate. The output ceilings that make these devices safe to sell without supervision also cap what they can do
• You have any of the “red flag” conditions the FDA requires manufacturers to warn about on the package and in the instruction brochure. These are the signs that mean see a clinician rather than buy a device
• Your hearing changed suddenly, or in one ear only, or came with pain, discharge, dizziness or ringing. Any of these warrants prompt medical attention, not shopping
• You want it to restore normal hearing. Eargo’s own footnote says it will not, and that applies across the category

On side effects: the FDA rule requires the instruction brochure to carry a warning about pain from device placement, cautions about excessive sound output, about components lodging in the ear, about hearing protection, and a note about reporting adverse events to the FDA. In practice the common complaints with in-canal devices are discomfort, occlusion, irritation and wax build-up. If a device hurts, stop using it and speak to a clinician.

How It Got Here

The wind-down did not come out of nowhere, and the path is documented in Eargo’s own SEC filings. We report it including the company’s denials, because they are part of the record.

Two things are worth holding together here. The $34.4 million settlement was about billing codes submitted to a federal insurance programme, not about whether the hearing aids worked — and Eargo denied the allegations and admitted no liability. At the same time, a company that pays $34.4 million while carrying a half-billion-dollar accumulated deficit and a formal going-concern warning is a company whose ability to stand behind a multi-year warranty was already a fair question in 2023.

The general lesson is worth more than the specific case. When you buy a device that depends on an app, firmware updates, proprietary consumables and a warranty, you are not just buying hardware — you are buying several years of the seller’s continued existence. For a public company that is checkable. Once a company deregisters, as this one did in 2024, it stops being checkable at all.

What the Evidence Says About Treating Hearing Loss

If this review talks you out of an Eargo, it should not talk you out of treating your hearing. So here is what the evidence actually supports, stated carefully, because this is an area where claims routinely outrun the data.

The honest summary: hearing loss is associated with cognitive decline — 2,497 indexed records address the link — but the trial designed to test whether treating it slows decline did not show that in its primary analysis. Anyone selling you a hearing aid on a dementia-prevention argument is going beyond the evidence.

Treat your hearing because you want to hear. That justification needs no trial. Following a conversation in a noisy restaurant, hearing a grandchild, not ending the day exhausted from concentrating — those are the benefits, they are immediate, and they are reason enough.

Why This Is on a Weight-Loss Site

Because a large share of our readers are managing type 2 diabetes or metabolic disease alongside their weight, and the link between diabetes and hearing loss is one of the better-studied associations in this space — 3,462 indexed records pair the two, with a further 663 pairing obesity with hearing loss.

We are describing an association, not a causal claim, and we have not run a trial-level review of it here. But the practical implication is uncontroversial and worth acting on: if you are living with diabetes, hearing is worth having checked as part of routine care, in the same way eyes and feet already are. That check is a hearing test with a professional, not a consumer device bought online.

Legitimacy and Credentials

That BBB entry is a small lesson in itself. An A+ accredited rating is not a solvency rating. It reflects complaint handling and responsiveness, not whether a company will exist next year, and here it sits on a profile that has not caught up with the news.

What to Consider Instead

We are not going to name a replacement brand. We have not reviewed the alternatives to the standard we apply here, and sending you from one unsupported device to an unverified one would repeat the mistake. What we can give you is the checklist we would use.

Who Should Buy, and Who Should Look Elsewhere

Who should buy an Eargo today:

• Nobody. We cannot construct a case. There is no manufacturer storefront, support is committed only to 15 September 2026, warranty administration after that is undetermined, replacement parts depend on remaining inventory, and firmware updates are explicitly unpromised
• The one marginal exception: an existing Eargo owner who wants a cheap second-hand backup of the same model to cannibalise for parts, at a price that reflects having no warranty. That is a spares decision, not a hearing-care decision

Look elsewhere if you are:

• Buying your first hearing aid. Get a hearing test, then choose a supported product
• Replacing a failing Eargo. The warranty window closes on 15 September; use it, then move on
• Attracted by a heavily discounted Eargo from a third-party seller. The discount is the market pricing in the absence of support
• Under 18. OTC hearing aids may not lawfully be sold to or for you
• Dealing with sudden, one-sided, or painful hearing changes. That is a clinical problem, today, not a purchase

Pros and Cons

Limitations of This Review

This is a fast-moving situation and this page is a snapshot of 11 August 2026. The notice itself says further information is expected within about 60 days. A buyer, an acquirer, or a third party may take over warranty administration; support may be extended; the site may change entirely. Check eargo.com and your email before acting on anything here, and treat the 15 September date as the company stated it, not as a prediction of what will actually happen.

We never tested a device. We have not worn an Eargo, measured its output, assessed sound quality, or evaluated the self-fitting software. Nothing here is a judgement on how well these hearing aids work. Everything about the product comes from FDA records and the company’s own published materials.

We could not verify any pricing, because there was no storefront to read, and we have therefore published no prices. Financial information comes from a Form 10-K for the year ended 31 December 2022 — the most recent available, and now well over three years old, because the company deregistered in 2024. The relationship between Eargo, Inc. and LXE Hearing is as described in Eargo’s notice; we have not examined the corporate structure. The DOJ matter was settled without any admission of liability and the allegations were denied; it should not be read as a finding.

On the clinical material: this review is general consumer information and is not medical advice. The ACHIEVE result is one trial in adults aged 70–84, 88% of whom were White, and its subgroup finding is hypothesis-generating rather than conclusive. The diabetes and obesity figures are counts of indexed literature describing associations, not evidence of causation, and we did not appraise those studies individually. Decisions about your hearing should be made with a doctor or audiologist who can examine you.

Frequently Asked Questions

Verdict

We should say clearly what this rating is and is not. It is not a safety alert. Eargo held FDA clearance K221698 as a self-fitting over-the-counter hearing aid, cleared under a Class II regulation whose special controls require clinical data on the self-fitting strategy and usability testing showing that real people can use the device correctly. The company’s own marketing footnote conceded that its products “will not restore normal hearing”, which is more honest than much of this category. And the DOJ matter that cost it $34.4 million concerned insurance billing codes, was denied, carried no admission of liability, and did not, on the company’s account, pertain to how the product performed.

The rating is about today. There is no storefront. Customer service is committed “through at least September 15th”. Warranty claims are processed if submitted by that date, and what happens afterwards is, in the company’s words, still being developed. Replacement tips, domes and wax guards depend on “available inventory and resources”. The app “will not be available indefinitely”, and the company’s own FAQ declines to say whether firmware updates will continue. Above all: “we cannot guarantee the availability of any future support services.”

A hearing aid is not a gadget you replace when you feel like it. It is a device you wear every day, that depends on consumable parts, an app and a warranty, and that people often save up for. Buying into a product line with a support horizon measured in weeks is not a bargain at any discount.

If you already own a pair, this page has a deadline in it. Submit any warranty claim before 15 September, order the consumables you will need, update the email address on your account so you receive whatever comes next, and start looking for a replacement while your current devices still work. Your Eargos will keep amplifying sound. What has gone is the company standing behind them.

And if this stops you buying a hearing aid altogether, that is the wrong lesson. Get your hearing tested. Not because of any dementia claim — the trial designed to test that returned p = 0.96 in its primary analysis — but because hearing the people around you is worth having, and because a proper examination finds the causes a consumer device never will.